Despite being less common than other forms of cardiac amyloidosis, Apo AI amyloidosis and Apo AIV amyloidosis often deserve diagnostic consideration, according to these investigators.

The diagnosis of cardiac amyloidosis is a challenging and time-consuming process for patients, with many going years without an accurate diagnosis, and losing critical time in the process.

Phase 3 – REVEAL study for iodine 124I-evuzamitide (AT-01) in patients with suspected cardiac amyloidosis has begun enrollment by Brigham and Women’s Hospital, Boston MA, in conjunction with ...

Reassessing Cardiac Amyloidosis: Sex Disparities in Diagnostic Thresholds —Recent findings challenge the traditional view of cardiac amyloidosis as predominantly a male disease, indicating ...

The document provides a diagnostic algorithm and emphasizes the need for a multidisciplinary, individualized approach for this under-recognized cause of heart failure.

Patients with cardiac amyloidosis have very poor survival without therapy. Diagnosis at early stages of the disease is crucial and there are many diagnostic tools for cardiac amyloidosis ...

Objectives Cardiac amyloidosis (CA) is a rare and underdiagnosed disease associated with a high mortality rate. Although, in ...

Cardiac amyloidosis is underrecognized in patients with heart failure; however, recent improvements in the understanding of this disease have led to developments in diagnosis and treatment.

Transthyretin amyloidosis, also called ATTR amyloidosis, is associated with accumulation of ATTR amyloid deposits in the heart and commonly manifests as progressive cardiomyopathy. Patisiran, an RN ...

Specifically, for TTR amyloidosis, there are a variety of orthopedic manifestations of the disease that can precede cardiac onset of disease.

A new expert consensus decision pathway published by the American College of Cardiology highlights the importance of recognizing and diagnosing cardiac amyloidosis at an early stage to allow the ...

124I-evuzamitide (AT-01) is one of the first investigational diagnostic imaging agents to receive Breakthrough Therapy Designation (BTD) from the US Food and Drug Administration (FDA), and the ...